Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform
February 11, 2010
Enigma Diagnostics Taps Tecan to Make and Market Forthcoming POC Molecular Dx Platform
Enigma struck the alliance with Tecan in anticipation of a fourth-quarter commercial launch of its miniaturized PCR instrument for point-of-care influenza diagnostic tests in Europe in partnership with GlaxoSmithKline.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- GSK to Market Enigma Diagnostics' POC Respiratory Disease Tests Under New Pact
August 10, 2011 / PCR Insider - Enigma Dx Begins Clinical Trials for Flu Test on Integrated MDx Platform
April 14, 2011 / PCR Insider - Dx Focus: Cepheid Xpert CT/NG; AITbiotech abTES Flu 4-Plex and MTB Real-Time Assays
January 3, 2013 / PCR Insider - Enigma and Tecan Expand OEM Pact to Develop High-Throughput MDx Platform for Third Party
January 13, 2011 / PCR Insider - As UK Patent Office Upholds Enigma's PCR Patents, Biogene Exec Says Dispute 'Far from Closed'
October 21, 2010 / PCR Insider